These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 23109014)

  • 1. HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: a randomised pilot study (KaMon study).
    Hasson H; Galli L; Gallotta G; Neri V; Blanc P; D'Annunzio M; Morsica G; Sollima S; Merli M; Lazzarin A; Uberti-Foppa C
    New Microbiol; 2012 Oct; 35(4):469-74. PubMed ID: 23109014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot, prospective, open-label simplification study to evaluate the safety, efficacy, and pharmacokinetics of once-daily lopinavir-ritonavir monotherapy in HIV-HCV coinfected patients: the MONOCO study.
    Cooper C; la Porte C; Tossonian H; Sampalis J; Ackad N; Conway B
    HIV Clin Trials; 2012; 13(4):179-88. PubMed ID: 22849960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting.
    d'Arminio Monforte A; Gianotti N; Cozzi-Lepri A; Pinnetti C; Andreoni M; di Perri G; Galli M; Poli A; Costantini A; Orofino G; Maggiolo F; Mazzarello G; Celesia BM; Luciani F; Lazzarin A; Sighinolfi L; Rizzardini G; Bonfanti P; Perno CF; Antinori A;
    Antivir Ther; 2014; 19(3):319-24. PubMed ID: 24036891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice.
    Moltó J; Santos JR; Negredo E; Miranda C; Videla S; Clotet B
    J Antimicrob Chemother; 2007 Aug; 60(2):436-9. PubMed ID: 17556354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
    AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation.
    Meraviglia P; Schiavini M; Castagna A; Viganò P; Bini T; Landonio S; Danise A; Moioli MC; Angeli E; Bongiovanni M; Hasson H; Duca P; Cargnel A
    HIV Med; 2004 Sep; 5(5):334-43. PubMed ID: 15369508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial.
    Spire B; Marcellin F; Cohen-Codar I; Flandre P; Boue F; Dellamonica P; Raffi F; Norton M; Van Philippe N; Delfraissy JF
    Antivir Ther; 2008; 13(4):591-9. PubMed ID: 18672538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen.
    Cahn P; Montaner J; Junod P; Patterson P; Krolewiecki A; Andrade-Villanueva J; Cassetti I; Sierra-Madero J; Casiró AD; Bortolozzi R; Lupo SH; Longo N; Rampakakis E; Ackad N; Sampalis JS
    PLoS One; 2011; 6(8):e23726. PubMed ID: 21886816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.
    Ma Q; Vaida F; Wong J; Sanders CA; Kao YT; Croteau D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; Morgello S; Simpson DM; Heaton RK; Grant I; Letendre SL;
    J Neurovirol; 2016 Apr; 22(2):170-8. PubMed ID: 26407716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.
    Bongiovanni M; Cicconi P; Landonio S; Meraviglia P; Testa L; Di Biagio A; Chiesa E; Tordato F; Bini T; Monforte Ad
    Int J Antimicrob Agents; 2005 Jul; 26(1):88-91. PubMed ID: 15878262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.
    Pulido F; Arribas JR; Delgado R; Cabrero E; González-García J; Pérez-Elias MJ; Arranz A; Portilla J; Pasquau J; Iribarren JA; Rubio R; Norton M;
    AIDS; 2008 Jan; 22(2):F1-9. PubMed ID: 18097218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management.
    Jones M; Núñez M
    Curr Opin HIV AIDS; 2011 Nov; 6(6):546-52. PubMed ID: 22001896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
    Ghosn J; Flandre P; Cohen-Codar I; Girard PM; Chaix ML; Raffi F; Dellamonica P; Ngovan P; Norton M; Delfraissy JF;
    HIV Med; 2010 Feb; 11(2):137-42. PubMed ID: 19682100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study).
    Gianotti N; Galli L; Maserati R; Sighinolfi L; Ripamonti D; Palvarini L; Lo Caputo S; Focà E; Celesia BM; Baldelli F; Sterrantino G; Lazzarin A
    New Microbiol; 2016 Oct; 39(4):290-294. PubMed ID: 27551725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavir.
    Palacios R; Vergara S; Rivero A; Aguilar I; Macías J; Camacho A; Lozano F; García-Lázaro M; Pineda JA; Torre-Cisneros J; Márquez M; Santos J
    HIV Clin Trials; 2006; 7(6):319-23. PubMed ID: 17197379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART.
    Bongiovanni M; Chiesa E; Di Biagio A; Meraviglia P; Capetti A; Tordato F; Cicconi P; Biasi P; Bini T; d'Arminio Monforte A
    J Antimicrob Chemother; 2005 Jun; 55(6):1003-7. PubMed ID: 15824089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Wirtz V; Rightmire A; Odeshoo L; McLaren C
    AIDS; 2006 Mar; 20(5):711-8. PubMed ID: 16514301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
    J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo study.
    Gianotti N; Poli A; Galli M; Pan A; Rizzardini G; Soria A; Viale P; Di Biagio A; Quirino T; Viganò P; Bonfanti P; d'Arminio Monforte A; Fortino I; Lazzarin A
    New Microbiol; 2014 Oct; 37(4):439-48. PubMed ID: 25387282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.